National asthma guidelines published in 2020 recommend that most patients with moderate-to-severe asthma would benefit from using one inhaler that includes both a long-term anti-inflammatory medicine and quick-relief medicine. This treatment is called SMART (or MART), which stands for Single Maintenance and Reliever Therapy. Studies show that using a single inhaler reduces the risk of asthma flare-ups by about 30%, compared to using one daily maintenance inhaler plus a separate, quick-relief inhaler as needed. However, only a small number of the 25 million people with asthma in the U.S. are prescribed and use SMART.
Read more
